1 / 25

Myasthenia Gravis

Myasthenia Gravis. Terri Kueber, CRNA, MS. Objectives . Explain the pathophysiology and classification of Myasthenia Gravis (MG) List the signs and symptoms and clinical manifestation Describe the various treatments available for Myasthenia Gravis

tudor
Download Presentation

Myasthenia Gravis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myasthenia Gravis Terri Kueber, CRNA, MS

  2. Objectives • Explain the pathophysiology and classification of Myasthenia Gravis (MG) • List the signs and symptoms and clinical manifestation • Describe the various treatments available for Myasthenia Gravis • Discuss the anesthetic considerations for patients with Myasthenia Gravis

  3. Introduction • Myasthenia Gravis is an autoimmune neuromuscular • Consider a “Snowflake Disease” • Cause is still unknown • No known cure • History • Incident and prevalence is increasing with 5-10 per 100,000  25,000 cases in US • Still considered sporadic • Women versus men • Often associated with other autoimmune disorders

  4. MGFA/Osserman Classification • Class I: Ocular weakness, other muscle are normal • Class II: Mild weakness affecting other muscle • Class IIa: Muscles weakness affecting limbs and possibly oropharyngeal muscles • Class III: Moderate weakness/severe ocular weakness • Class IV: Severe weakness affecting limb muscle • Class V: Defined by intubation

  5. Pathophysiologic Type • Ocular Myasthenia Gravis • Classic General Myasthenia Gravis • Transient Neonatal Myasthenia Gravis • Juvenile Myasthenia Gravis • Congenital Types • Drug-induced (Pencillamine, NDMR, aminoglycosides, procainamide)

  6. Presenting Symptoms • Bilateral or Unilateral Ptosis • Diplopia • Hoarseness • Altered Speech • Problems chewing • Dysphagia • Limited Facial Expressions

  7. Diagnostic Procedures • Endrophonium (tensilon) Chloride Test • 2.6-3.3 mg initial dose Neostigmine may be used in patients who do not respond to tensilon • Auto-antibodies in MG – receptor binding antibodies are present in 80% of patients • Thymic hyperplasia is present in 70%

  8. Diagnostic Procedures (continue) • Electromyography (EMG) Testing • Repetitive Nerve Stimulation (RNS) • Single Fiber EMG (SFEMG) • Ocular Cooling • Other Testing

  9. Differential Diagnosis • Congenital Myasthenia Syndromes (not autoimmune) • Drug induced MG • Eaton-Lambert Syndrome (related to Small cell carcinoma of the lung) • Hyperthyroidism (increases MG symptoms) • Graves disease • Botulism • Ophthalmoplegia • Intracranial pathology

  10. Factors that Worsen MG • Fatigue or insufficient sleep • Stress, anxiety, illness • Overexertion, repetitive motion • Pain or depression • Low potassium or thyroid levels • Alcoholic beverages • Sudden fear, or extreme anger • Extreme temperatures • Humidity • Sunlight or bright lights • Hot foods or beverages • Medications (beta blockers, antibiotics, calcium blockers) • Chemicals such as household cleaner, insecticides, pet sprays, lawn chemicals

  11. Treatment for Myasthenia Gravis • Cholinesterase inhibitor • Pyridostigmine – most commonly used • Neostigmine – used less frequently • Thymectomy • Plasmapheresis • Corticoid Steroid Therapy • Immunosuppressive therapy (azathioprine, cyclosporine, etc.) • Short-term Immunotherapy (IV immunoglobulin)

  12. Anesthetic Comsiderations • Current health and symptoms • PMH/PSH • NMBA – Monitoring • Post operative plan • Pain control • Induction and Extubation criteria

  13. Case Discussion #1 • 46 year old male diagnosis with MG in 6/2006 • Presenting symptoms: fatigue and weakness after working out with intermittent dipoplia • At time of diagnosis weakness lead to respiratory failure leading ventilation and respiratory support x 3 days • Residual symptoms: weakness, pain and left ptosis • Refractory to medical support under went a thymectomy in October 2009

  14. Case Discussion (Continued) • Height/Weight: 75”/95=4.7 • PFT’s FVC=65%, FEV1/FVC=61% • Did not take his Pyridostigmine this am as he was instructed not to take it (not by anesthesia department)

  15. What did we do?? • Gave Pyridostigmine 90 mg preoperatively IV • Additional dose give at 1400 in recovery room • Induction included: slow induction no neuromuscular blocking agents Total Agents included: Propofol 400mg Fentanyl 300 Morphine 4mg Midazolam 3 mg Intubation with glidescope secondary to NIM’s tube placement.

  16. Patient Outcome • Successfully extubated at end of case • Received pyridostigmine in recovery room • ICU overnight • Discharge next day.

  17. Case Discussion #2 • 63 year old male • Diagnosis between 12/05 and 2/06 • Schedule for Laparoscopic Nissen Fundoplication • Multiple drug allergies • Ex-smoker (2 PPD x 30 years) • H/O: MG controlled with medications, HTN, diet controlled, AST – normal with EF 55-65% • Hiatal Hernia/Barrett’s Esophagus • Previous surgery included: Brow lift, Laparoscopic Cholecystectomy

  18. How did the case finish?? • Previous anesthetic records • Surgeons desire muscle relaxation • We did: • Propofol 350mg • Fentanyl 400 mcg • Midazolam 2 mg • Zofran/Decadron • Ephedrine 15mg • Vasopressin 2 units Patient’s was successfully extubated in OR and discharge home the next day

  19. Thank you for your attention Questions??

More Related